[A20-109] Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2021
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Patients with cystic fibrosis from 6 to 11 years of age who are homozygous for the F508del mutation in the CFTR gene
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.